# Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

> **NCT03282396** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03282396
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-08
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03282396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03282396, "Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03282396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*